The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial

被引:0
|
作者
Uchida, Yoshiaki [1 ]
Kaneda, Tomomi [1 ]
Ono, Mio [1 ]
Matsuoka, Masao [2 ]
Nakamura, Utano [3 ]
Ishida, Akiko [3 ]
Yamasaki, Yoshimitsu [4 ]
Takeo, Hiroki [5 ]
Sakurai, Takanobu [1 ]
机构
[1] Mitsubishi Corp Life Sci Ltd, Res & Dev Div, 1-1-3 Yurakucho,Chiyoda Ku, Tokyo 1000006, Japan
[2] M&I Sci CORP, 1-17-26 Nakatsu,Kita Ku, Osaka 5310073, Japan
[3] Pharm Foods Int Co Ltd, 1-49 Goryo-Ohara,Nishikyo Ku, Kyoto 6158245, Japan
[4] NISHI UMEDA Clin Asian Med Collaborat, 3-3-45 Umeda,Kita Ku, Osaka 5300001, Japan
[5] TAKEO Clin, Med Corp Diastep, 4-22-7 Taishido,Setagaya Ku, Tokyo 1540004, Japan
关键词
cysteine peptide; glutathione; cysteinylglycine; & gamma; -glutamylcysteine; skin brightness; safety; GLUTATHIONE METABOLISM; PIGMENTATION; BIOSYNTHESIS;
D O I
10.3390/cosmetics10030072
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glutathione (GSH) is present in almost all human cells and has a beneficial effect on human skin brightness. Cysteinylglycine (Cys-Gly) and ?-glutamylcysteine (?-Glu-Cys) are GSH synthesis components. In this study, we defined glutathione (GSH), cysteinylglycine (Cys-Gly), and ?-glutamylcysteine (?-Glu-Cys) as cysteine peptide and performed a randomized, double-blind, placebo-controlled study to investigate the effects of orally administered cysteine peptide on human skin brightness using a CM-26d portable spectrophotometer in healthy males and females aged between 20 and 65 years old. Eligible participants were randomly allocated into three groups (cysteine peptide 45 mg: n = 16, 90 mg: n = 15, and placebo: n = 16). Each subject ingested six tablets every day for 12 weeks, and skin brightness was measured at 0, 4, 8, and 12 weeks. As a result, the 45 mg group exhibited arm brightening in a time-dependent manner, and a significant difference was observed compared to the placebo at week 12 (p = 0.028). Moreover, no serious adverse events and changes related to 270 mg study food were observed in the safety trial. Here, we suggest that cysteine peptide is a promising and safe compound for human skin brightness.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] The clinical effect of benesco™ on reflux symptoms: A double-blind randomized placebo-controlled trial
    Kuipers, Thijs
    Oude Nijhuis, Renske A. B.
    Schuitenmaker, Jeroen M.
    Bredenoord, Albert J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (10):
  • [42] THE CLINICAL EFFECT OF BENESCOTM ON REFLUX SYMPTOMS: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Kuipers, Thijs
    Berndien, Renske Anne
    Nijhuis, Oude
    Schuitenmaker, Jeroen M.
    Bredenoord, Arjan
    GASTROENTEROLOGY, 2023, 164 (06) : S586 - S586
  • [43] FELODIPINE IN HEART-FAILURE - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY IN 23 PATIENTS
    DUNSELMAN, PHJM
    KUNTZE, CEE
    VANBRUGGEN, A
    LIE, KI
    DRUGS, 1987, 34 : 79 - 80
  • [44] Effects of daily intake of Harudori-kombu: A randomized, double-blind, placebo-controlled, parallel-group study
    Nishimura, Mie
    Sugawara, Miwako
    Kudo, Masafumi
    Kinoshita, Yasunori
    Yoshino, Hiroyuki
    Nishihira, Jun
    FUNCTIONAL FOODS IN HEALTH AND DISEASE, 2019, 9 (04): : 205 - 223
  • [45] A Randomized, Double-Blind, Placebo-Controlled Clinical Effect of a Xanthone-rich Dietary Supplement on Immune Function in Humans: A Randomized Double-Blind Placebo-Controlled Trial
    Tang, Yu-Ping
    Li, Peng-Gao
    Ji, Hongping
    Kou, Yan
    FASEB JOURNAL, 2008, 22
  • [46] Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
    Kapoor, Raju
    Furby, Julian
    Hayton, Thomas
    Smith, Kenneth J.
    Altmann, Daniel R.
    Brenner, Robert
    Chataway, Jeremy
    Hughes, Richard A. C.
    Miller, David H.
    LANCET NEUROLOGY, 2010, 9 (07): : 681 - 688
  • [47] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [48] Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial
    Goudie, Andrew R.
    Lipworth, Brian J.
    Hopkinson, Pippa J.
    Wei, Li
    Struthers, Allan D.
    LANCET RESPIRATORY MEDICINE, 2014, 2 (04): : 293 - 300
  • [49] A randomized, double-blind and placebo-controlled crossover trial on the effect of L-ornithine ingestion on the human circadian dock
    Fukuda, Takafumi
    Haraguchi, Atsushi
    Takahashi, Masaki
    Nakaoka, Takashi
    Fukazawa, Mayuko
    Okubo, Jin
    Ozaki, Mamiho
    Kanatome, Ayana
    Ohya, Rena
    Miura, Yutaka
    Obara, Kuniaki
    Shibata, Shigenobu
    CHRONOBIOLOGY INTERNATIONAL, 2018, 35 (10) : 1445 - 1455
  • [50] Visceral Fat-Reducing Effect and Safety of Continuous Consumption of Beverage Containing Resistant Maltodextrin: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial
    Kitagawa, Machiko
    Nakagawa, Shinsuke
    Suzuki, Takuto
    Kishimoto, Yuka
    Kanahori, Sumiko
    Hatakeyama, Yoshitaka
    Tomita, Shimpei
    Fukuhara, Ikuo
    JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 2020, 66 (05) : 417 - 426